Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (9835)	10/21/1997 11:18:00 AM
From: Henry Niman	Respond to of 32384

Although Ligand wasn't listed in the NY Times "Company Index" for today's stories, the did carry the AP article on LLY's earnings, which of course had quite a bit of info on the LGND deal: "Lilly also announced Monday it has entered into a strategic alliance with Ligand Pharmaceuticals Inc. to develop new products to treat advanced diabetes, cardiovascular and related therapies. Lilly will get the rights to Targretin, an oral therapy currently in early clinical development for Type II diabetes; two second generation oral diabetes compounds in preclinical development; and the rights to Ligand's metabolic disease technology to develop more advanced diabetes, cardiovascular and related therapies. "